relatlimab+nivolumab

DRUG2 trials

Sponsors

Bristol-Myers Squibb, Regeneron Pharmaceuticals

Conditions

Melanoma

Phase 2

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Active, not recruitingNCT06101134

Bristol-Myers SquibbMelanoma

Start: 2023-11-06End: 2026-12-21Updated: 2026-09-14

Phase 3

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

RecruitingNCT06246916

Regeneron PharmaceuticalsMelanoma

Start: 2024-09-09End: 2033-07-10Target: 560Updated: 2026-08-19

Related Papers

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Clinical Cancer Research2024-10-183 citations

A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.

Journal of Clinical Oncology2024-06-012 citations

A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.

Journal of Clinical Oncology2024-06-011 citations